Hematologic Malignancies clinical trials

Explore recruiting hematologic malignancies clinical trials.

Recruiting hematologic malignancies studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hematologic Malignancies trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies

Italy, Germany, Greece, Hungary

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Study to Assess the Effect of Food on the Pharmacokinetics of CA-4948 in Healthy Male Subjects

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

An Open-Label, Multicenter, Extension Study to Provide Continued Treatment for Patients with Hematologic Malignancies Previously Enrolled in Studies with Tafasitamab.

Italy, Spain, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations.

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

CAR123 T cell treatment of relapsed/refractory hematologic malignancies.

Czechia

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Hungary, Spain, Czechia, Sweden, Denmark, Greece +1 more

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Hematologic Malignancies trials by city

Hematologic Malignancies in Toronto Hematologic Malignancies in Vancouver Hematologic Malignancies in Montreal Hematologic Malignancies in Calgary Hematologic Malignancies in Edmonton Hematologic Malignancies in Ottawa Hematologic Malignancies in Winnipeg Hematologic Malignancies in Quebec City Hematologic Malignancies in Hamilton Hematologic Malignancies in Kitchener Hematologic Malignancies in London Hematologic Malignancies in Halifax Hematologic Malignancies in New York Hematologic Malignancies in Los Angeles Hematologic Malignancies in Chicago Hematologic Malignancies in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease